

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 16 (2006) 5551-5554

## Design of inhibitors against guanase: Synthesis and biochemical evaluation of analogues of azepinomycin

Ravi K. Ujjinamatada, Anila Bhan<sup>†</sup> and Ramachandra S. Hosmane\*

Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA

> Received 8 July 2006; revised 4 August 2006; accepted 7 August 2006 Available online 22 August 2006

Abstract—As part of a program to design rational, mechanism-based inhibitors of guanase, we report here the synthesis and biochemical screening of two analogues of azepinomycin (1 and 2), a naturally occurring inhibitor of guanase, known to mimic the transition-state of the enzyme-catalyzed reaction. Our biochemical results show that compounds 1 and 2 are competitive inhibitors with  $K_i$  of  $2.01 \pm 0.16 \times 10^{-5}$  and  $5.36 \pm 0.14 \times 10^{-5}$  M, respectively. © 2006 Elsevier Ltd. All rights reserved.

Guanine deaminase (GDA) or guanase (EC 3.5.4.3) is an enzyme that catalyzes the hydrolytic deamination of guanine to xanthine. This enzyme has been found in human liver, brain, and kidney.<sup>1</sup> There have been reports of abnormally high levels of serum guanase activ-ity in patients with liver diseases,<sup>2–4</sup> and so, the elevated enzyme activity has been suggested as a marker of hepatitis and hepatoma.<sup>3</sup> Furthermore, such a high guanase activity is believed to be a biochemical indicator of rejection in liver transplant recipients.<sup>5</sup> Increased levels of guanase have also been detected in cancerous kidney<sup>6–8</sup> and breast cancer tissues.<sup>7,9</sup> In addition, patients with multiple sclerosis exhibit significantly elevated levels of guanase activity in their cerebral spinal fluids.<sup>10</sup> These observations suggest that a potent guanase inhibitor is necessary for exploring the biochemical mechanisms of the above metabolic disorders as well to understand the specific physiological role played by guanase, and not to mention its potential therapeutic use in treating these disorders. While many studies on guanase inhibition have been reported in the literature, 11-36 a potent guanase inhibitor with a submicromolar or nanomolar  $K_i$  has yet to be discovered. We report here the design, synthesis, and guanase inhibitory activity of two

analogues (1 and 2) of the natural product azepinomycin, a moderate inhibitor of guanase, which is believed to mimic the transition state of the enzyme-catalyzed deamination reaction.<sup>37</sup>



Guanase catalyzes the hydrolysis of guanine (3) to xanthine (4) (Scheme 1) via the tetrahedral intermediate (5).<sup>38</sup> The recently solved crystal structure of guanase<sup>39</sup> from *Bacillus subtilis* suggests that the enzyme-catalyzed reaction is assisted by an active site zinc metal ion (Zn<sup>2+</sup>), which forms a tetrahedral complex with His-53, Cys-83, and Cys-86 of the protein, as well as with an isolated water molecule. Glutamate-55 serves as a proton shuttle, abstracting a proton from the zinc-activated water to form the necessary hydroxide nucleophile, while also enabling protonation at the N-3 site of guanine, thus resulting in the formation of the intermediate 5, as shown. Glu-55 also assists in protonation of the NH<sub>2</sub> group of 5, facilitating the elimination of a molecule of ammonia to form the final product

*Keywords*: Guanase (guanine deaminase); Inhibitors; Azepinomycin analogues; Synthesis; Biochemical studies.

<sup>\*</sup> Corresponding author. Tel.: +1 410 455 2520; fax: +1 410 455 1148; e-mail: hosmane@umbc.edu

<sup>&</sup>lt;sup>†</sup> Present address: G.E Healthcare, BioSciences, Protein Separations, 800 Centennial Ave, Piscataway, NJ 08855, USA.



Scheme 1.  $Zn^{2+}$ -assisted hydrolysis of guanine to xanthine, catalyzed by guanase.

xanthine.<sup>39</sup> Azepinomycin may interrupt this hydrolytic process via coordination of its own OH group at position –6 with the active site zinc, displacing the crucial active site water molecule involved in hydrolysis.

The above zinc-mediated hydrolysis of guanine to xanthine, catalyzed by guanase, led us to the design of the title inhibitors of this paper. In view of only a moderate inhibition of guanase by azepinomycin,<sup>37</sup> which suggested somewhat weak binding of the inhibitor to the enzyme via zinc metal coordination, we hypothesized that the additional metal coordination sites on the inhibitor would strengthen its binding to the protein, and hence enhance its inhibitory potential. The introduction of a carbonyl group at position-5 of the heterocycle, coupled with movement of the 6-hydroxy group away from the ring by an additional carbon atom, would allow excellent coordination of the inhibitor with  $Zn^{2+}$ to form a stable, 6-membered ring structure. The latter would use two of the four metal coordination sites, while the other two would be occupied by two of the three original amino acid residues at the enzyme active site, as depicted in Scheme 2 (Note: the two amino acids



Scheme 2. The proposed pathway for inhibition of guanase by the title analogues of azepinomycin.

shown to be bonded to the metal are only arbitrary). With this rationale, we set out to synthesize our target inhibitors 1 and 2. The substitution of a benzyl group at position-3 of 1 was to explore if a hydrophobic moiety in that position would enhance, lower, or unaffect the strength of enzyme binding. In our earlier guanase inhibition studies involving planar, aromatic ring-expanded purine bases, we had noticed that a benzyl group at the N-3 position often potentiated the enzyme inhibition.<sup>30,32</sup>

The target compound  $1^{40}$  was synthesized (Scheme 3) by two different methods, both by reduction mediated by a mixture of lithium borohydride and super hydride in THF at 0 °C. The first method employed 3-benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6Himidazo[4,5-e][1,4]diazepine-5,8-dione (6)<sup>20</sup> as the starting material, while the second method used 3-benzyl-4,5,7,8-tetrahydro-6-methoxycarbonyl-6H-imidazo[4,5e][1,4]diazepine-5,8-dione (7).<sup>41</sup> The detailed multi-step synthesis of both compounds 6 and 7 has been reported by us several years ago, 20,41 employing a common starting material, 1-benzyl-5-nitroimidazole-4-carboxylic acid.<sup>20</sup> The target compound  $2^{40}$  was prepared by debenzylation of 1 using catalytic hydrogenation with palladium hydroxide in acetic acid at 40 psi. The target compounds were characterized by <sup>1</sup>H and <sup>13</sup>C NMR, and mass spectral data, along with elemental microanalyses.

Guanase from rabbit liver (purchased from Sigma–Aldrich) was employed in the biochemical studies. All studies were carried out at 25 °C and pH 7.4 by spectroscopic measurements of the rate of hydrolysis of the substrate guanine at  $\lambda_{max}$  245 nm. The change in optical density at  $\lambda_{max}$  245 nm per unit time is a measure of the guanase activity. A total of seven different concentrations of the substrate, ranging from 5 to 20  $\mu$ M, was employed for each inhibitor concentration that was either 8 or 25  $\mu$ M, while the amount of enzyme in each assay was  $7.67 \times 10^{-3}$  unit. The Lineweaver–Burk plots (1/V vs 1/S) (see Figs. 1A and B) were used to



Scheme 3. Synthesis of the target compounds 1 and 2.



Figure 1. (A) Lineweaver–Burk plot of target compound 1. (B) Lineweaver–Burk plot of target compound 2.

calculate  $K_{\rm m}$ ,  $V_{\rm max}$ , and  $K_{\rm i}$ . Our biochemical results showed that  $K_{\rm m}$  of enzyme with guanine as substrate was  $0.966 \times 10^{-5}$  M. The target compounds **1** and **2** both showed competitive inhibition with  $K_{\rm i}$  of  $2.01 \pm 0.16 \times 10^{-5}$  and  $5.36 \pm 0.14 \times 10^{-5}$  M, respectively. These results suggest that the presence of a benzyl group at position-3 (compound **1**) enhances the inhibitory activity by greater than twofold as compared to that without the benzyl group (compound **2**).

Inhibitory activities  $(K_i)$  of the target compounds 1 and **2** are roughly comparable to that of azepinomycin  $(IC_{50} = 0.5 \times 10^{-5} \text{ M})$ ,<sup>37</sup> especially considering that the inhibition for the latter is reported only as  $IC_{50}$ , which being specific to the conditions of the assay such as concentrations of the substrate and the enzyme is often somewhat lower than the actual  $K_i$  value.<sup>42</sup> The observed inhibition data suggest that the introduction of an additional  $Zn^{2+}$  coordination site on azepinomycin nucleus has little effect on the enzyme inhibition. There are multiple possibilities to explain these observed results, including but not limited to: (a) The mechanism of GDA inhibition by either azepinomycin or its analogues 1 and 2 may not involve the active site  $Zn^{2+}$  coordination. This is a distinct possibility in view of their moderate  $K_i$  values as compared to, for example, that of the structurally analogous pentostatin (2'-deoxycoformycin), another 5:7-fused imidazo[4,5-d][1,3]diazepine ring system containing an exocyclic hydroxy group.<sup>43</sup> Pentostatin, unlike azepinomycin, is an extremely tight-binding, totally irreversible inhibitor of adenosine deaminase (ADA) with a  $K_i$  ranging from  $10^{-11}$  to  $10^{-13}$  M,<sup>43</sup> and whose X-ray structure complexed with the protein clearly shows coordination of its hydroxy group with an active site zinc metal ion.44,45 (b) Another possibility is that both azepinomycin and its analogues 1 and 2 coordinate with the active site zinc but the ligand-metal interaction is not as strong

as in pentostatin because of possibly imperfect relative placements of the ligand and the metal at the enzyme active site. The best answer may come from the X-ray structure of a complex of azepinomycin or one of its analogues with a mammalian guanase.

## Acknowledgments

The research was supported in part by grants (# 5 RO1 AI55452 & #1 R21 AI071802) from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, Bethesda, Maryland, and by an unrestricted grant from Nabi Biopharmaceuticals, Rockville, Maryland.

## **References and notes**

- Knights, E. M., Jr.; Whitehouse, J. L.; Hue, A. C.; Santos, C. L. J. Lab. Clin. Med. 1965, 65, 355.
- Nishikawa, Y.; Fukumoto, K.; Watanabe, F.; Yoshihara, H. *Rinsho. Byori.* 1989, 37, 1392.
- Shiota, G.; Fukada, J.; Ito, T.; Tsukizawa, M.; Yamada, M., et al. Jpn. J. Med. 1989, 28, 22.
- 4. Ito, S.; Tsuji, Y.; Kitagawa, N.; Akihiko, I.; Syundo, J., et al. *Hepatology* **1988**, *8*, 383.
- 5. Crary, G. S.; Yasmineh, W. G.; Snover, D. C.; Vine, W. *Transplant. Proc.* **1989**, *21*, 2315.
- Durak, I.; Beduk, Y.; Kavutcu, M.; Suzer, O.; Yaman, O., et al. *Cancer Invest.* 1997, 15, 212.
- Yuan, G.; Bin, J. C.; McKay, D. J.; Snyder, F. F. J. Biol. Chem. 1999, 274, 8175.
- 8. Paletzki, R. F. Neuroscience 2002, 109, 15.
- Canbolat, O.; Durak, I.; Cetin, R.; Kavutcu, M.; Demirci, S., et al. Breast Cancer. Res. Treat. 1996, 37, 189.
- Kaneshige, Y.; Matsumoto, H.; Chiba, S.; Hashimoto, S.; Noro, H. *Rinsho. Shinkeigaku.* 1989, 29, 854.
- 11. Baker, B. R. J. Med. Chem. 1967, 10, 59.
- 12. Baker, B. R.; Santi, D. V. J. Med. Chem. 1967, 10, 62.

- 13. Baker, B. R.; Siebeneick, H. U. J. Med. Chem. 1971, 14, 802.
- 14. Baker, B. R.; Siebeneick, H. U. J. Med. Chem. 1971, 14, 799.
- 15. Baker, B. R.; Wood, W. F. J. Med. Chem. 1967, 10, 1106.
- 16. Baker, B. R.; Wood, W. F. J. Heterocycl. Chem. 1967, 10, 1101.
- 17. Baker, B. R.; Wood, W. F. J. Med. Chem. 1968, 11, 650.
- 18. Baker, B. R.; Wood, W. F. J. Med. Chem. 1968, 11, 644.
- 19. Baker, B. R.; Wood, W. F. J. Med. Chem. 1969, 12, 216.
- 20. Bhan, A.; Hosmane, R. S. Tetrahedron Lett. 1994, 35, 6831.
- 21. Bhan, A.; Hosmane, R. S. Nucleosides Nucleotides 1995, 14, 455.
- 22. Dietrich, L. S.; Shapiro, D. M. J. Biol. Chem. 1953, 203, 89.
- Kanzawa, F.; Hoshi, A.; Kuretani, K. Chem. Pharm. Bull. 1971, 19, 1737.
- 24. Kanzawa, F.; Hoshi, A.; Nishimoto, T.; Kuretani, K. *Chem. Pharm. Bull.* **1970**, *18*, 392.
- 25. Kumar, S.; Josan, V.; Sanger, K. C. S.; Tewari, K. K.; Krishnan, P. S. *Biochem. J.* **1967**, *102*, 691.
- Lucacchini, A.; Bazzichi, L.; Biagi, G.; Livi, O.; Segnini, D. Ital. J. Biochem. 1982, 31, 153.
- Lucacchini, A.; Montali, U.; Segnini, D. Ital. J. Biochem. 1977, 26, 27.
- Lucacchini, A.; Segnini, D.; Da Settimo, A.; Livi, O. Ital. J. Biochem. 1979, 28, 194.
- 29. Meyer, R. B., Jr.; Skibo, E. B. J. Med. Chem. 1979, 22, 944.
- 30. Rajappan, V.; Hosmane, R. S. Bioorg. Med. Chem. Lett. 1998, 8, 3649.
- Rajappan, V. P.; Hosmane, R. S. Nucleosides Nucleotides 1998, 17, 1141.
- Rajappan, V. P.; Hosmane, R. S. Nucleosides Nucleotides 1999, 18, 835.
- Saxena, A. K.; Ahmad, S.; Shanker, K.; Bhargava, K. P.; Kishor, K. *Pharmazie* 1980, *35*, 16.
- 34. Saxena, A. K.; Ahmad, S.; Shanker, K.; Kishor, K. *Pharmacol. Res. Commun.* **1984**, *16*, 243.
- 35. Silipo, C.; Hansch, C. J. Med. Chem. 1976, 19, 62.
- Wang, L.; Hosmane, R. S. Bioorg. Med. Chem. Lett. 2001, 11, 2893.
- 37. Isshiki, K.; Takahashi, Y.; Iinuma, H.; Naganawa, H.; Umezawa, Y., et al. J. Antibiot. (Tokyo) **1987**, 40, 1461.
- Lewis, A. S.; Glantz, M. D. J. Biol. Chem. 1974, 249, 3862.
  Liaw, S.-H.; Chang, Y.-J.; Lai, C.-T.; Chang, H.-C.;
- Chang, G.-G. J. Biol. Chem. 2004, 279, 35479. 40. Preparation and physicochemical properties of the target

compounds are as follows: **3-Benzyl-4,5,7,8-tetrahydro-6-hydroxymethyl-6H-imidazo-**[**4,5-e**][**1,4]diazepine-5,8-dione (1)**. Method A: 3-Benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6H-imidazo [4,5-e][1,4]diazepine-5,8-dione (**6**).<sup>20</sup> (50 mg, 0.159 mmol) was placed in a flame-dried three-necked flask. Anhydrous THF (10 mL) and LiBH<sub>4</sub> (10 mg, 0.45 mmol) were added. The reaction mixture was stirred at 0 °C for 10 min, and then 1 M super hydride (0.05 mL) was added. The ice bath was removed and the reaction mixture was refluxed with stirring for 5 h. It was slowly cooled to room temperature. Methanol (5 mL) was added and the pH of the mixture was carefully brought to 7.0 with 1 N HCl. The reaction mixture was adsorbed on silica gel (1 g), loaded onto a flash silica gel column, and eluted with a mixture of chloroform-methanol (6:1). The appropriate fractions were pooled and evaporated to obtain a white solid. Yield 23 mg, 51%;  $R_f = 0.24$  (chloroformmethanol, 5:1); mp 169-171 °C; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  10.95 (s, 1H, CONH, D<sub>2</sub>O exchangeable), 7.68 (s, 1H, imidazole CH), 7.51 (s, 1H, CONH, D<sub>2</sub>O exchangeable), 7.35-7.13 (m, 5H, C<sub>6</sub>H<sub>5</sub>), 5.26 (s, 2H, CH<sub>2</sub>), 4.75 (s, 1H, OH, D<sub>2</sub>O exchangeable), 3.72 (m, 1H, CH), 3.62 (m, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz. DMSO $d_6$ ):  $\delta$  169.1, 163.8, 136.31, 136.0, 131.7, 128.7, 127.7, 126.9, 122.7, 58.4, 55.1, 46.6; HRMS (FAB) calcd for  $C_{14}H_{14}N_4O_3$ , 286.1065 (M<sup>+</sup>); observed m/z 287.1058 (MH<sup>+</sup>). Anal. Calcd for C<sub>14</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>: C, 58.73; H, 4.93; N, 19.57. Found: C, 58.55; H, 5.05; N, 19.28.

*Method B*: The title compound was prepared in 42% yield from 3-benzyl-4,5,7,8-tetrahydro-6-methoxy-carbonyl-6*H*-imidazo[4,5-*e*][1,4]diaze-pine-5,8-dione (7),<sup>41</sup> using the procedure described above in Method A. The isolated product was identical in all aspects, including m.p.,  $R_{\rm f}$ , <sup>1</sup>H NMR, <sup>13</sup>C NMR, and Mass spectral data.

4,5,7,8-Tetrahydro-6-hydroxymethyl-6H-imidazo[4,5-e] [1,4]diazepine-5,8-dione (2): A mixture of 1 (46 mg, 0.16 mmol) and palladium hydroxide (30 mg, 0.2 mmol) in glacial acetic acid (5 mL) was hydrogenated in a Parr hydrogenator at 40 psi for 18 h. The reaction mixture was filtered through Celite. The Celite cake was washed with methanol and the filtrate was evaporated to dryness. The residue was triturated with ether. The precipitated solid was filtered and washed with ether. Yield 21 mg (63 %);  $R_{\rm f} = 0.15$ (methanol-chloroform, 7:3); light brown solid: mp>250 °C; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  0.72 (s, 1H, CONH, D<sub>2</sub>O exchangeable), 7.6 (s, 1H, imidazole CH), 7.51 (s, 1H, CONH, D<sub>2</sub>O exchangeable), 4.75 (s, 1H, OH, D<sub>2</sub>O exchangeable), 3.65 (m, 3H, CH and CH<sub>2</sub>);  $^{13}$ C NMR (100 MHz, DMSO-*d*<sub>6</sub>): δ 168.9, 162.2, 137.9, 125.4, 112.5, 59.4, 56.5; HRMS (FAB), calcd. for C<sub>7</sub>H<sub>8</sub>N<sub>4</sub>O<sub>3</sub>, 196.0596 (M<sup>+</sup>); obsd. m/z 197.0587 (MH<sup>+</sup>); Anal. Calcd for C<sub>7</sub>H<sub>8</sub>N<sub>4</sub>O<sub>3</sub>: C, 42.86; H, 4.11; N, 28.56. Found: C, 42.97; H, 4.16; N, 28.45.

- 41. Bhan, A.; Hosmane, R. S. J. Heterocycl. Chem. 1993, 30, 1453.
- Robers, D. A.; Ward, W. H. J. Enzyme Inhibitors. In Medicinal Chemistry: Principles and Practice, 2nd ed.; The Royal Society of Chemistry: Cambridge, UK, 2002; pp 70–71.
- Agarwal, R. P.; Cha, S.; Crabtree, G. W.; Parks, R. E., Jr. Coformycin and deoxycoformycin: tight-binding inhibitors of adenosine deaminase. In *Chemistry and Biology of Nucleosides and Nucleotides*; Academic Press: New York, 1978; pp 159–197.
- 44. Hosmane, R. S.; Hong, M. Biochem. Biophys. Res. Commun. 1997, 236, 88.
- 45. Wang, Z.; Quiocho, F. A. Biochemistry 1998, 37, 8314.